ResearchPeptide
Cagrilintide
Published Research
PubMed-indexed studies for Cagrilintide
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.
View on PubMed →Development of Cagrilintide, a Long-Acting Amylin Analogue.
View on PubMed →Amylin analogs for the treatment of obesity without diabetes: present and future.
View on PubMed →Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
View on PubMed →Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
View on PubMed →Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity.
View on PubMed →Research-Grade Cagrilintide
⚠️ For laboratory research only. Not for human use.